| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/27/2008 | WO2008015273A8 Cd4-receptor-derived peptides and method for the preparation thereof |
| 03/27/2008 | WO2008013962A9 Method and mixture for in-vivo photochemical cross-linking of collagen |
| 03/27/2008 | WO2008012089A3 Polyphenol/peptide composition and use thereof for promoting gastric health |
| 03/27/2008 | WO2008009437A3 Sdf-i binding nucleic acids |
| 03/27/2008 | WO2008005686A3 Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| 03/27/2008 | WO2007149550A3 Modulation of differentiation and cell function via fox01 and notch signaling |
| 03/27/2008 | WO2007142818A3 Use of a soluble morphogenic protein complex for treating cartilage defects |
| 03/27/2008 | WO2007130642A3 Modulation of nkg2d |
| 03/27/2008 | WO2007115837B1 Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule |
| 03/27/2008 | WO2007107328A3 Subcutaneous implants containing a degradation-resistant polylactide polymer and a lh-rh analogue |
| 03/27/2008 | WO2007071363A3 METHODS OF USING THE CALCINEURIN A VARIANT Cnaβ1 |
| 03/27/2008 | WO2007056435A3 Dynamin mediated diseases and associated methods and products |
| 03/27/2008 | WO2006065960A3 Cationic liposomes comprising a charge neutral compound and a cationic phospholipid |
| 03/27/2008 | WO2004069200A3 Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases |
| 03/27/2008 | WO2003075845A3 Immunogenicity of glucan binding protein |
| 03/27/2008 | WO2001022921A3 Prevention of atherosclerosis and undesired blood clotting by reducing von willebrand factor |
| 03/27/2008 | US20080077372 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 03/27/2008 | US20080077252 Muscle-Based Grafts/Implants |
| 03/27/2008 | US20080076906 Antagonists of neuropilin receptor function and use thereof |
| 03/27/2008 | US20080076904 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
| 03/27/2008 | US20080076817 Neurotrophic N-glyoxyl-prolyl ester compounds e.g. 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; non-immunosuppressive; side effect reduction; neurodegenerative diseases |
| 03/27/2008 | US20080076752 substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein |
| 03/27/2008 | US20080076731 Control of NK cell function and survival by modulation of ship activity |
| 03/27/2008 | US20080076721 Use of branched chain fatty acid amino acid salts and compositions thereof |
| 03/27/2008 | US20080076720 a combinations of niacinamide for dry skin, improve skin aging, resist to wrinkle; treating skin disorders |
| 03/27/2008 | US20080076719 oligopeptides derived from human chorionic gonadotropin (hCG); compositions exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell |
| 03/27/2008 | US20080076718 oligopeptide or polypeptide amino acid sequences as biodrug antitumor agents, anticarcinogenic agents; treating autoimmune diseases, AIDS, inflammatory diseases, cardiovascular disorder of ischemic processes, allograft rejection, cerebral strokes, traumas, burns, Alzheimer's disease, Parkinson's disease |
| 03/27/2008 | US20080076717 Polypeptides for bone mineralization |
| 03/27/2008 | US20080076716 Anti-Microbial Defensin-Related Peptides and Methods of Use |
| 03/27/2008 | US20080076715 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 03/27/2008 | US20080076714 oral or mucosal administration for treating immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases; drug delivery method |
| 03/27/2008 | US20080076713 Peptides selectively lethal to malignant and transformed mammalian cells |
| 03/27/2008 | US20080076712 Before cardiopulmonary bypass surgery or coronary artery bypass grafting; injecting a polypeptide preferential inhibitor of kallikrein, rather than aprotinin |
| 03/27/2008 | US20080076711 Therapeutic agents for osteopenia |
| 03/27/2008 | US20080076710 covalently attached to a nonpeptide polyoxyethylene glycol moiety; nucleic acids encoding the polypeptides; reducing the number of copies of a virus in infected cells; drugs/polymer conjugates/ as viricides treating Hepatitis-C virus |
| 03/27/2008 | US20080076709 Isolated polypeptide, encoded by nucleic acid sequence, a vector from Staphylococcus; use for activators or inhibitors in therapy, antigen for vaccination, antibodies; antibacterial agent treating Staphylococcus infections; biodrugs |
| 03/27/2008 | US20080076708 Active Variants of the Il-18 Binding Protein and Medical Uses Thereof |
| 03/27/2008 | US20080076707 Topically administering cyclosporin A; lupus, multiple sclerosis, skin disorders, oral diseases, autoimmune diseases, respiratory system disorders; antiulcer agents, anticarcinogenic agents, antiarthritic agents |
| 03/27/2008 | US20080076706 stimulate proliferation and differentiation of hematopoietic cells in animal, by administering an isolated PEGylated granulocyte colony stimulating factor comprising a cysteine variants; drugs/polymer conjugates/; bone marrow transplantation, infection with the human immunodeficiency virus, neutropenia |
| 03/27/2008 | US20080076705 Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents |
| 03/27/2008 | US20080076704 Delivering therapeutic formulation containing N-sulphated-N,O-carboxymethylchitosan as a primary carrier across a membrane that has limited permeability for therapeutic agent |
| 03/27/2008 | US20080076703 Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| 03/27/2008 | US20080076702 synergistic coagulants comprising the mixture of a preparation of Blood Factor VII or related polypeptide and a preparation of factor VIII (antihemophilic factor) or related polypeptide; high speed coagulants in one dosage form; kits; hemostatic agents |
| 03/27/2008 | US20080076701 double stranded ribonucleic acid is conjugated to the peptide; interfering ribonucleic acid with a delivery peptide; biodrug treating influenza in animal, inflammation occurs in arthritis, psoriasis |
| 03/27/2008 | US20080076700 Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone |
| 03/27/2008 | US20080076672 Methods for Identifying Genes Essential to the Growth of an Organism |
| 03/27/2008 | US20080076175 Generating transgenic lymphoid cell comprising sequences coding immunoglobulin epitope for use in tissue targeted therapies |
| 03/27/2008 | US20080076172 Vectors for tissue-specific replication |
| 03/27/2008 | US20080076150 Isolating preferential protein from tissue extract using acidic washes and centrifugation |
| 03/27/2008 | US20080076136 Nucleotide sequences coding transport protein for use in identifying modulators for treatment of pain; flavor enhancement |
| 03/27/2008 | US20080075798 Facial tissues |
| 03/27/2008 | US20080075782 Comprising a stabilizing polyol and a bioactive agent, wherein the composition provides quick release of the bioactive agent after administration; inhalation through the mouth; drug delivery; osteoporosis treatment |
| 03/27/2008 | US20080075755 Macular degeneration, choroidal or retinal neovascularization, or ocular inflammation; administering a poxvirus viral complement interfering protein (VCIP) |
| 03/27/2008 | US20080075750 Methods for producing three-dimensional tissue-engineered cardiac constructs and uses regarding same |
| 03/27/2008 | US20080075742 synergistic biomedical activity as immunostimulants; biodrugs for prevention and/or treatment of cancer, treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances; adverse side effects of irradiation |
| 03/27/2008 | US20080075737 inducing an immune response to an HIV antigen; genetic engineered polypeptide; inserted into cell; improves or restores the blood clotting time, blood disorders; gene therapy |
| 03/27/2008 | US20080075730 Methods and compositions for treating biofilms |
| 03/27/2008 | US20080075729 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 03/27/2008 | US20080075728 Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation |
| 03/27/2008 | US20080075725 Novel Immunointeractive Molecules and uses Thereof |
| 03/27/2008 | US20080075724 Nucleotide sequeces coding protein for use in the detection, diagnosis and treatment cell proliferative, autoimmune diseases, inflammation and infection; biodrugs as antiinflammatory agents, antiproliferative agents |
| 03/27/2008 | US20080075722 detecting the presence of a protein marker in patient sample, using a reagent which specifically binds with protein; comparing the copy number of a minimal common region; anticarcinogenic biodrugs |
| 03/27/2008 | US20080075721 Method of treating fibrosis |
| 03/27/2008 | US20080075718 biodegradable oligomers or polymers used for the controlled, localized and sustained delivery of drugs |
| 03/27/2008 | US20080075714 Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| 03/27/2008 | US20080075713 isomerase enzymes and ATP-binding cassette (ABC) transport proteins, used for controlling metabolism of triglycerides; diagnosis, prevention and treatment of metabolic disorders |
| 03/27/2008 | US20080075711 used in the treatment or prophylaxis of bleeding episodes, coagulation disorders and maintain or enhance haemostasis; blood disorders |
| 03/27/2008 | US20080075710 Herbal composition for treating hangovers |
| 03/27/2008 | US20080075709 used in the treatment or prophylaxis of bleeding episodes and coagulation disorders; synergistic |
| 03/27/2008 | US20080075708 compounds having an anchoring domain that anchors the compound to the surface of target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as viruses; neuraminidase |
| 03/27/2008 | US20080075707 topical administration or injection of hydrolase enzymes for restoring or maintaining the strength and thickness of aging skin |
| 03/27/2008 | US20080075706 Pharmaceutical formulation |
| 03/27/2008 | US20080075703 using a mixture of cells including connective tissue cells transfected or transduced with genes encoding transforming growth factors or bone morphogenic proteins, used for regenerating cartilage and treatment of osteoarthritis; somatic cell gene therapy; tissue-targeted therapy |
| 03/27/2008 | US20080075697 administering therapeutic effective dose of human interferon-beta mutein (hIFN- beta ser17), two times per week or three times per week by intramuscular injection |
| 03/27/2008 | US20080075696 Treatment Of Hepatitis C In The Asian Population With Interferon-Beta |
| 03/27/2008 | US20080075695 Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein |
| 03/27/2008 | US20080075693 Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| 03/27/2008 | US20080075692 prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production |
| 03/27/2008 | US20080075691 Permucosal Composition and Method of Improving Permucosal Absorption |
| 03/27/2008 | US20080075690 tumor necrosis factor alpha (TNF alpha ) mutein attached to substrates, to create an adsorbent matrix, that permit binding of immune system inhibitors such as soluble TNF receptors, thereby inducing a vigorous immune response while minimizing toxicity |
| 03/27/2008 | US20080075689 a mixture of vinyl copolymers and cosmetically acceptable carriers, used as skin cleaning compounds in the form of hair gel, shampoo, setting foam, hair tonic, hair sprays or hair foams; cosmetics |
| 03/27/2008 | US20080075672 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 03/27/2008 | US20080075667 Nanoparticles, nanocapsules and nanogels |
| 03/27/2008 | US20080075666 Methods and compositions for treating diastolic dysfunction |
| 03/27/2008 | US20080075662 Novel Method for Analyzing Nucleic Acid Et Use Thereof for Evaluating the Degree of Mrna Editing of the Serotonin 5-Ht2c Receptor |
| 03/27/2008 | US20080075657 Forming a biocompatible hydrogel in situ; adding a liquid premix of alkylated chitosan and an oxidized polysaccharide in an aqueous medium into an intervertebral disc, hydrogel induces tissue growth within the disc |
| 03/27/2008 | DE102006046411A1 Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von akutem Lungenversagen (ALI) Drugs for the prophylaxis or treatment or diagnosis of acute lung injury (ALI) |
| 03/27/2008 | DE102006046410A1 Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten Drugs for the prophylaxis or treatment or diagnosis of ischemic diseases |
| 03/27/2008 | CA2700360A1 In vivo transformation of pancreatic acinar cells into insulin-producing cells |
| 03/27/2008 | CA2664064A1 Internally-constrained cyclic oligopeptides |
| 03/27/2008 | CA2663819A1 Phytases, nucleic acids encoding them and methods for making and using them |
| 03/27/2008 | CA2663795A1 Pulmonary surfactant formulations and methods for promoting mucus clearance |
| 03/27/2008 | CA2663547A1 Method of treating endothelial dysfunction |
| 03/27/2008 | CA2663545A1 Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
| 03/27/2008 | CA2663377A1 Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| 03/27/2008 | CA2663323A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | CA2663272A1 Composition for the treatment of amyotrophic lateral sclerosis |
| 03/27/2008 | CA2663074A1 Protease resistant insulin analogues |
| 03/27/2008 | CA2663055A1 Aldehyde tags, uses thereof in site-specific protein modification |
| 03/27/2008 | CA2662374A1 Compositions and uses thereof for the treatment of wounds |